CAAS Capital Management’s CalciMedica CALC Stock Holding History

CAAS Capital Management’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-714	Closed	-$290K	–	1173
2020 Q4	$290K	Hold	714	–	–	﹤0.01%	730
2020 Q3	$127K	Buy	+714	New	+$149K	﹤0.01%	452

Other funds holding CALC

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AlpInvest Partners Amsterdam, Netherlands $49.7M AUM 23.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAAS Capital Management's CALC Position: Q1 2021 in Review

CAAS Capital Management sold out of CalciMedica (CALC) in Q1 2021, closing a stake of 714 shares — an estimated $290K sold.

CAAS Capital Management first reported a position in CALC in Q3 2020 and held it in 2 quarters. The position peaked at $290K in Q4 2020. 51 funds tracked by Wall St. Rank hold CALC as of Q1 2021.

CAAS Capital Management reported no remaining CalciMedica position as of Q1 2021 after selling out during the quarter.
CAAS Capital Management sold 714 CalciMedica shares in Q1 2021, an estimated $290K.
CAAS Capital Management first reported a position in CalciMedica in Q3 2020 and held it in 2 quarters.
CAAS Capital Management's CalciMedica position peaked at $290K in Q4 2020.
51 funds tracked by Wall St. Rank held CalciMedica as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.